

Defined Approaches for Predicting GHS and EPA Eye Irritation Classification of Agrochemicals

Amber Daniel, MTox

**Inotiv, contractor supporting the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods
(NICEATM)**

**ASCCT-ESTIV Award Winners Webinar
April 24, 2025**

This project was funded in part with federal funds from the National Institute of Environmental Health Sciences, National Institute of Health, under Contract Nos. HHSN273201500010C to Integrated Laboratory Systems LLC, an Inotiv company and HHSN273201400020C to MRIGlobal (Kansas City, MO), and by National Institutes of Health Intramural Research Project ES103386-01, Research Operations Supporting the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods.

Outline




INTRODUCTION



STUDY DESIGN



RESULTS &
ANALYSES



CONCLUSIONS

Conflict of Interest Statement

The authors declare that there exist no actual or potential conflicts of interest.

Introduction



Alternatives to animal testing for eye irritation have historically been assessed by direct comparison with Draize rabbit eye test




Rabbit test has been demonstrated to lack reproducibility and human relevance



Movement away from direct comparisons in favor of evaluating based on reliability and human-relevance of the method


Defined Approaches (DAs): A rule-based data interpretation procedure that is applied to data generated with a defined method(s) to derive a prediction.

- No expert judgment is required.
- DAs can achieve an equivalent or better predictive capacity than that of the animal test to predict responses in humans.



US EPA Office of
Pesticide Programs

PETA Science Consortium
International, e.V.



NIEHS/DTT/NICEATM

1. Assess the applicability of in vitro methods to agrochemical formulations

2. Develop DAs that leverage strengths of these methods to predict the complete spectrum of eye irritancy potential

Study Design

Phase 1

Assess validity of test methods

Phase 2

Refine test methods for potential use
in defined approaches

Phase 3

Expand the number of formulations
classified as mild or moderate
irritants based on the in vivo test

29 agrochemical formulations selected based on:

- Availability of historical rabbit data or ocular irritancy classification information.
- Representation of common agrochemical formulation types (i.e., emulsifiable concentrate, suspension concentrate, soluble liquids).
- Representation of the full range of GHS and EPA hazard classifications.

Assays/protocols evaluated:

- ▪ BCOP - OP-KIT opacitometer in vitro irritancy score (w/ histopathology)
- BCOP - extended incubation in vitro irritancy score (w/ histopathology)
- BCOP - laser light-based opacitometer irritation score (w/ histopathology)
- ▪ EpiOcular - standard protocol
- EpiOcular - time-to-toxicity neat
- EpiOcular - time-to-toxicity diluted
- neutral red release
- isolated chicken eye
- porcine cornea reversibility assay
- ▪ SkinEthic time-to-toxicity for liquids
- ▪ EyeIRR-IS
- in vitro depth of injury - neat protocol
- in vitro depth of injury - diluted protocol

Full NICEATM report available at:
<https://doi.org/10.22427/NTP-NICEATM-1>

Selection of Assays for Inclusion in DAs

| Test Method | OECD TG | Human Relevant |
|--|---------|----------------|
| Bovine corneal opacity and permeability (BCOP) with histopathological depth of injury evaluation | 437 | - |
| EpiOcular™ Eye Irritation Test (EO) | 492 | Yes |
| SkinEthic™ time-to-toxicity for liquids (TTL) | 492B | Yes |
| EyeIRR-IS | - | Yes |

Developing DAs

DAs for EPA Classification of Agrochemicals:

CUTANEOUS AND OCULAR TOXICOLOGY
2024, VOL. 43, NO. 1, 58-68
<https://doi.org/10.1080/15569527.2023.2275029>




RESEARCH ARTICLE

OPEN ACCESS [Check for updates](#)


Defined approaches to classify agrochemical formulations into EPA hazard categories developed using EpiOcular™ reconstructed human corneal epithelium and bovine corneal opacity and permeability assays

Anna J. van der Zalm^a, Amber B. Daniel^b, Hans A. Raabe^c, Neepa Choksi^{b*}, Tara Flint Silva^d, Julie Breeden-Alemi^d, Lindsay O'Dell^e, Nicole C. Kleinstreuer^f, Anna B. Lowit^e, David G. Allen^b and Amy J. Clippinger^a

Consider physical and chemical properties of substance to select a test system



Consider physical and chemical properties of substance to select a test system




GHS and EPA Labeling Requirements

| | GHS | | | | EPA | | | |
|--|-------|-----------------------------|-------------------------------|---------------|-------|---|--|--------------------------------|
| | Cat.* | Signal Word | Hazard Statement | Pictogram | Cat.* | Signal Word | Hazard Statement | PPE Labeling |
| Corrosive | 1 | DANGER | Causes severe eye damage. | | I | DANGER | Corrosive. Causes irreversible eye damage. | Appropriate protective eyewear |
| Moderate Irritant | 2A | WARNING | Causes severe eye irritation. | | II | WARNING | Causes substantial but temporary eye injury. | Appropriate protective eyewear |
| Mild Irritant | 2B | WARNING | Causes eye irritation. | None required | III | CAUTION | Causes moderate eye irritation. | None required [†] |
| Non-corrosive/ Minimal Irritant | NC | No hazard labeling required | | | IV | No hazard or PPE labeling required [†] | | |


*Based on in vivo results and associated decision criteria that are distinct for each system. [†]Registrant may choose to include, if appropriate.
Abbreviations: Cat. = category; NC = not classified; PPE = personal protective equipment.

DAs for **GHS** and **EPA** Classification of Agrochemicals:


DA-BCOP+




DA-EO+




DA-TTL+




DA-EyeIRR-IS+







| OP-KIT Opacitometer In Vitro Irritation Score (IVIS) | GHS Classification |
|--|---------------------------------------|
| IVIS ≤ 3 | NC |
| 3 < IVIS | No stand-alone prediction can be made |
| IVIS > 55 | 1 |



Adapted from Redden et al. 2009:

| Histopathological Findings | | GHS Classification |
|---|------------|--------------------|
| Damage or loss limited to the surface squamous cell layer in the epithelium; wing cell and basal cell layers intact | “Minimal” | NC |
| Damage or loss extends to the wing cell layers in the epithelium; basal cell layer and basal lamina intact | “Mild” | 2B |
| Damage involves all layers of the epithelium and may cause keratocyte damage to the upper third to half of the stroma | “Moderate” | 2A |
| Keratocyte damage extends into the lower half of the stroma and may include damage to the endothelium | “Severe” | 1 |



Data Analysis

- Given the limitations and low reliability of the in vivo test, it was not appropriate to assess performance of the DAs based on direct concordance with the rabbit test data.
- Instead, we conducted orthogonal concordance analyses. For each formulation, we:
 - Used in vitro test data to apply the DAs.
 - Orthogonally compared the GHS and EPA classifications predicted by the DAs and by the historical rabbit test data against each other.
 - Evaluated orthogonal concordance based on agreement across the five approaches.
 - Orthogonally concordant if the prediction aligned with the prediction of at least two other approaches (i.e., at least 3 of 5 approaches achieved the same “majority prediction”).
 - Orthogonally discordant if the prediction misaligned with the majority prediction.
 - Also evaluated whether orthogonal discordance affected hazard labeling (GHS) or PPE labeling (EPA).

Main Results: GHS

- Majority prediction determined for **97%** of formulations.
- Orthogonal concordance of DAs **82-93%** (vs. 71% historical in vivo).
- Hazard labeling: All DAs produced fewer underprotective predictions than historical in vivo.

| Formulation Code | DA-BCOP+ | DA-EO+ | DA-TTL+ | DA-EyeIRR-IS+ | Historical In Vivo | Majority Prediction |
|--|-------------------|-------------------|-------------------|-------------------|--------------------|---------------------|
| A | NC | NC | NC | NC | NC | NC |
| B | NC | NC | NC | NC | NC | NC |
| C | NC | NC | NC | NC | NC | NC |
| D | 1 | 1 | 1 | 1 | 1 | 1 |
| E | 2B | 2B | 2B | 1 | 1 | 2B |
| F | 1 | 1 | 1 | 1 | 1 | 1 |
| G | 1 | 1 | 1 | 1 | 1 | 1 |
| H | 1 | 1 | 1 | 1 | 1 | 1 |
| I | 1 | 1 | 1 | 1 | 1 | 1 |
| J | 1 | 1 | 1 | 1 | 1 | 1 |
| K | NC | 2B | 2B | 2B | 2A | 2B |
| L | NC | 2B | 2B | NC | NC | NC |
| M | NC | NC | NC | NC | NC | NC |
| N | NC | NC | NC | NC | NC | NC |
| O | NC | 2B | 2B | NC | NC | NC |
| P | NC | NC | NC | NC | NC | NC |
| Q | 2A ^a | 2A | 2A | 2A | NC | 2A |
| R | 2A | 2A | 1 | 1 | 2A | 2A |
| S | 2B ^a | 2B | 2B | 2B | 2B | 2B |
| T | 2B ^a | NC | 2B | NC | NC | NC |
| U | 2A | 2A | 2A | 1 | 2A | 2A |
| V | 1 ^b | 1 ^b | 1 ^b | 1 ^b | 2B | 1 |
| W | 2B | 2B | 2B | 2B | NC | 2B |
| X | 2A | 2A | 2A | 1 | 2A | 2A |
| Y | 2B ^a | 2B | 2B | 2B | 2A | 2B |
| Z | 2B | NC | NC | NC | NC | NC |
| AA | NC | 2B | 2B | 2B | 2A | 2B |
| AB | 2A | 2A | Not tested | Not tested | 2B | None |
| AC | 2B | 2B | 2B | NC | NC | 2B |
| Orthogonally concordant | 24/28; 86% | 26/28; 93% | 24/28; 86% | 23/28; 82% | 20/28; 71% | |
| Orthogonally discordant | 4/28; 14% | 2/28; 7% | 4/28; 14% | 5/28; 18% | 8/28; 29% | |
| Hazard labeling maintained ^c | 0 | 0 | 1 | 4 | 5 | |
| Hazard labeling overprotective ^c | 2 | 2 | 3 | 0 | 0 | |
| Hazard labeling underprotective ^c | 2 | 0 | 0 | 1 | 3 | |

^aIVIS < 3, but histopathology DoI analysis led to a more severe classification.

^bOptional histopathology DoI analysis would lead to a less severe classification (i.e., GHS Cat. II).

^cRelative to that of the majority prediction.

Orthogonally concordant prediction

Orthogonally discordant prediction;
hazard labeling maintained

Orthogonally discordant prediction;
hazard labeling overprotective

Orthogonally discordant prediction;
hazard labeling underprotective

Main Results: EPA

- Majority prediction determined for **97%** of formulations.
- Orthogonal concordance of DAs **75-93%** (vs. 79% historical in vivo).
- PPE labeling: All DAs produced fewer underprotective predictions than historical in vivo.

| Formulation Code | DA-BCOP+ | DA-EO+ | DA-TTL+ | DA-EyeIRR-IS+ | Historical In Vivo | Majority Prediction |
|---|-------------------|-------------------|-------------------|-------------------|--------------------|---------------------|
| A | IV | IV | IV | IV | IV | IV |
| B | IV | IV | IV | IV | IV | IV |
| C | IV | IV | IV | IV | IV | IV |
| D | I | I | I | I | I | I |
| E | III | III | III | I | I | III |
| F | I | I | I | I | I | I |
| G | I | I | I | I | I | I |
| H | I | I | I | I | I | I |
| I | I | I | I | I | I | I |
| J | I | I | I | I | I | I |
| K | IV | III | III | III | II | III |
| L | IV | III | III | IV | III | III |
| M | IV | IV | IV | IV | IV | IV |
| N | IV | IV | IV | IV | IV | IV |
| O | IV | III | III | IV | IV | IV |
| P | IV | IV | IV | IV | IV | IV |
| Q | II ^a | II | II | II | II | II |
| R | II | II | I | I | II | II |
| S | III ^a | III | III | III | III | III |
| T | III ^a | IV | III | IV | III | III |
| U | II | II | II | I | II | II |
| V | I ^b | I ^b | I ^b | I ^b | III | I |
| W | III | III | III | III | III | III |
| X | II | II | II | I | II | II |
| Y | III ^a | III | III | III | II | III |
| Z | III | IV | IV | IV | III | IV |
| AA | IV | III | III | III | II | III |
| AB | II | II | Not tested | Not tested | III | None |
| AC | III | III | III | IV | III | III |
| Orthogonally concordant | 24/28; 86% | 26/28; 93% | 26/28; 93% | 21/28; 75% | 22/28; 79% | |
| Orthogonally discordant | 4/28; 14% | 2/28; 7% | 2/28; 7% | 7/28; 25% | 6/28; 21% | |
| PPE labeling maintained ^c | 4 | 2 | 2 | 5 | 1 | |
| PPE labeling overprotective ^c | 0 | 0 | 0 | 2 | 4 | |
| PPE labeling underprotective ^c | 0 | 0 | 0 | 0 | 1 | |

| |
|---|
| Orthogonally concordant prediction |
| Orthogonally discordant prediction; PPE labeling maintained |
| Orthogonally discordant prediction; PPE labeling overprotective |
| Orthogonally discordant prediction; PPE labeling underprotective |


^aIVIS < 3, but histopathology DoI analysis led to a more severe classification.
^bOptional histopathology DoI analysis would lead to a less severe classification (i.e., EPA Cat. II).
^cRelative to that of the majority prediction.

Summary/Conclusions

- These DAs are **equally or more protective** of human health than the in vivo test.
- These DAs present an opportunity to **fully replace** the use of the in vivo test for determining GHS and EPA hazard classification and labeling of agrochemical formulations.

DA-BCOP+


BCOP



| Depth of Injury | GHS Category | EPA Category | Depth of Injury | GHS Category | EPA Category | Depth of Injury | GHS Category | EPA Category |
|-----------------|--------------|--------------|-----------------|--------------|--------------|-----------------|--------------|--------------|
| Minimal | NC | IV | Minimal | 2B | III | Minimal | 2A | II |
| Mild | 2B | III | Mild | 2A | II | Mild | 1 | I |
| Moderate | 2A | II | Moderate | 1 | I | Severe | 1 | I |
| Severe | 1 | I | Severe | 1 | I | Severe | 1 | I |

DA-EO+


EO



| Depth of Injury | GHS Category | EPA Category | Depth of Injury | GHS Category | EPA Category | Depth of Injury | GHS Category | EPA Category |
|-----------------|--------------|--------------|-----------------|--------------|--------------|-----------------|--------------|--------------|
| Minimal | 2B | III | Minimal | 2A | II | Minimal | 1 | I |
| Mild | 2A | II | Mild | 1 | I | Severe | 1 | I |
| Moderate | 2A | II | Moderate | 1 | I | Severe | 1 | I |
| Severe | 1 | I | Severe | 1 | I | Severe | 1 | I |

DA-TTL+


TTL



| Depth of Injury | GHS Category | EPA Category | Depth of Injury | GHS Category | EPA Category | Depth of Injury | GHS Category | EPA Category |
|-----------------|--------------|--------------|-----------------|--------------|--------------|-----------------|--------------|--------------|
| Minimal | 2B | III | Minimal | 2A | II | Minimal | 1 | I |
| Mild | 2A | II | Mild | 1 | I | Severe | 1 | I |
| Moderate | 2A | II | Moderate | 1 | I | Severe | 1 | I |
| Severe | 1 | I | Severe | 1 | I | Severe | 1 | I |

DA-EyeIRR-IS+

EyeIRR-IS



| Depth of Injury | GHS Category | EPA Category | Depth of Injury | GHS Category | EPA Category | Depth of Injury | GHS Category | EPA Category |
|-----------------|--------------|--------------|-----------------|--------------|--------------|-----------------|--------------|--------------|
| Minimal | 2B | III | Minimal | 2A | II | Minimal | 1 | I |
| Mild | 2A | II | Mild | 1 | I | Severe | 1 | I |
| Moderate | 2A | II | Moderate | 1 | I | Severe | 1 | I |
| Severe | 1 | I | Severe | 1 | I | Severe | 1 | I |



National Institute of
Environmental Health Sciences
Division of Translational Toxicology

Acknowledgments



Co-authors

- Anna van der Zalm, PSCI
- Hans Raabe, IIVS
- Amy Clippinger, PSCI
- Neepa Choksi, formerly of Inotiv-NICEATM
- Emily Reinke, Inotiv-NICEATM
- Dave Allen, formerly of Inotiv-NICEATM
- Nicole Kleinstreuer, NICEATM

Testing Labs

- EpiSkin
- IIVS
- ImmunoSearch
- Lebrun Labs
- MatTek

Agrochemical Companies

- BASF
- Bayer
- Corteva
- Syngenta

Other Collaborators/Contributors

- Julie Breeden-Alemi, EPA/OPP
- Tara Flint, EPA/OPP
- Lindsay O'Dell, EPA/OPP
- Monique Perron, EPA/OPP
- Anna Lowit, EPA/OPPT
- Elizabeth Farley-Dawson, Inotiv-NICEATM
- Kim To, formerly of Inotiv-NICEATM



Amber.Daniel@inotiv.com